B of A Securities Upgrades Akero Therapeutics (AKRO)
Fintel reports that on January 30, 2025, B of A Securities upgraded their outlook for Akero Therapeutics (NasdaqGS:AKRO) from Neutral to Buy. Analyst Price Forecast Suggests 23.34% Upside As of January 28,
Akero Therapeutics price target raised to $109 from $42 at UBS
UBS raised the firm’s price target on Akero Therapeutics (AKRO) to $109 from $42 and keeps a Buy rating on the shares. Akero reported “strong”
Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.8% on Analyst Upgrade
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan Stanley raised their price target on the stock from $46.00 to $96.00. Morgan Stanley currently has an overweight rating on the stock.
The Akero Therapeutics Inc Rollercoaster: What’s Behind the Latest AKRO Stock Fluctuation?
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $54 which represents a slight increase of $2.53 or 4.92% from the prior close of $51.47. The stock opened at $52.48 and touched a low of $51.
Akero Therapeutics upgraded to Buy from Neutral at BofA
BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow
Why Akero Therapeutics, Inc.’s (AKRO) Stock Is Up 97.52%
Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to sell.
Akero Therapeutics Inc (AKRO) Stock: More Resilient Than It Appears
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $51.71 which represents a slight increase of $25.53 or 97.52% from the prior close of $26.18. The stock opened at $57.26 and touched a low of $48.
J.P. Morgan Keeps Their Buy Rating on Akero Therapeutics (AKRO)
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Akero Therapeutics (AKRO – Research Report) on January 27 and set a price target of
GlobalData on MSN3d
Akero’s cirrhosis treatment shows promise in Phase IIb study
In subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.
STAT1d
RFK Jr.’s confirmation hearings, MASH drugs, and a controversial obesity ad
Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
Akero Therapeutics Reports Positive Results from SYMMETRY Study in Recent 8-K Filing
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
Akero Therapeutics Stock Doubles on Liver Data
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers for the offering. UBS Investment Bank is acting as co-manager for the offering.
Zacks.com on MSN2d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
BioPharma Dive2d
BioAge drops obesity drug; Akero, 89bio cash in on MASH data
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio ...